Thomas Gammill
Physician Assistant · Albuquerque, NMNPI 1760459333
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.5% of the total across 196 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 25 manufacturers reported payments, led by AstraZeneca at 28.2% of the total. Reporting peaked in 2022 at $1,201 and has fallen 66.2% since, to $406 in 2025. Among physician assistant clinicians in NM with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 196 payments — averaging $20.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- AbbVie$822
- Lilly USA, LLC$438
- Novo Nordisk$336
- Amarin Pharma, Inc.$176
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$152
- plus $1K from 19 others
What the payments were for
- Food & beverage$4,07599%
- Education$221%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 25 | $1,157 |
| AbbVie(2 entities) | 58 | $822 |
| Lilly USA, LLC | 24 | $438 |
| Novo Nordisk | 19 | $336 |
| Amarin Pharma, Inc. | 14 | $176 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 9 | $152 |
| Exact Sciences | 6 | $142 |
| Astellas Pharma US Inc | 5 | $127 |
| Neurelis, Inc. | 1 | $106 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 5 | $102 |
| Merck | 5 | $83 |
| Pfizer | 4 | $73 |
| Idorsia Pharmaceuticals US Inc | 4 | $71 |
| Acella Pharmaceuticals, LLC | 4 | $62 |
| Abbott | 3 | $44 |
| Lundbeck LLC | 1 | $29 |
| Novartis | 1 | $25 |
| Angiodynamics, Inc. | 1 | $25 |
| Teva Pharmaceuticals USA, Inc. | 1 | $24 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $23 |
| Eisai Inc. | 1 | $17 |
| Otsuka America Pharmaceutical, Inc. | 1 | $17 |
| Avion Pharmaceuticals | 1 | $16 |
| Alnylam Pharmaceuticals Inc. | 1 | $15 |
| GSK | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,097 in reported general payments places this provider in the 95th percentile of 635 physician assistant providers in New Mexico.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 51 | $63,042 |
| XifaxanRifaximin | 17 | $53,680 |
| FarxigaDapagliflozin Propanediol | 30 | $42,404 |
| MounjaroTirzepatide | 33 | $41,972 |
| RybelsusSemaglutide | 15 | $29,382 |
| TrulicityDulaglutide | 27 | $27,736 |
| EliquisApixaban | 15 | $20,236 |
| MyrbetriqMirabegron | 24 | $13,965 |
| JardianceEmpagliflozin | 13 | $12,222 |
| OxycontinOxycodone Hcl | 13 | $11,001 |
| SymbicortBudesonide/Formoterol Fumarate | 17 | $8,466 |
| Bevespi AerosphereGlycopyrrolate/Formoterol Fum | 13 | $7,564 |
| VascepaIcosapent Ethyl | 14 | $7,114 |
| ProgesteroneProgesterone, Micronized | 76 | $3,855 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 83 | $3,597 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $336 | $92,42466 claims |
| Lilly USA, LLCMounjaro, Trulicity | $438 | $69,70860 claims |
| AstraZenecaFarxiga, Symbicort, Bevespi Aerosphere | $1,157 | $58,43460 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $152 | $53,68017 claims |
| PfizerEliquis | $73 | $20,23615 claims |
| Astellas Pharma US IncMyrbetriq | $127 | $13,96524 claims |
| AbbVieArmour Thyroid | $822 | $2,94127 claims |
| Acella Pharmaceuticals, LLCNp Thyroid | $62 | $2,21634 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 635 physician assistant providers in New Mexico.
Other physician assistant in Albuquerque
- Leigh HigginsAlbuquerque$10K
- Maria AbeytaAlbuquerque$8K
- Kari LavigneAlbuquerque$8K
- Elizabeth BelitzAlbuquerque$8K
- Desiree BarelaAlbuquerque$6K
- Stephanie BeyesAlbuquerque$5K
- Stephanie GonzalesAlbuquerque$5K
- Miquela WiegelAlbuquerque$5K
- Gabriela PobarAlbuquerque$5K
- Jacklyn ChavezAlbuquerque$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.